HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prolongation of the atrioventricular conduction in fetuses exposed to maternal anti-Ro/SSA and anti-La/SSB antibodies did not predict progressive heart block. A prospective observational study on the effects of maternal antibodies on 165 fetuses.

AbstractOBJECTIVES:
We prospectively examined the prevalence and outcome of untreated fetal atrioventricular (AV) prolongation in the presence of maternal anti-Ro antibodies.
BACKGROUND:
It has been suggested that antibody-mediated congenital complete atrioventricular block (CAVB) may be preventable if detected and treated early when low-grade block is present. With this rationale in mind, dexamethasone has been advocated by others to treat prolonged fetal AV conduction >2 z-scores, consistent with first-degree heart block.
METHODS:
Between July 2003 and June 2009, 165 fetuses of 142 anti-Ro/La antibody-positive women were referred to our center for serial echocardiography. Our protocol included weekly evaluation of the fetal AV conduction between 19 (range 17 to 23) and 24 (range 23 to 35) gestational weeks. AV times were compared with institutional reference data and with post-natal electrocardiograms.
RESULTS:
Of 150 fetuses with persistently normal AV conduction throughout the observation period, a diagnosis of CAVB was subsequently made in 1 at 28 weeks, after the serial evaluation had ended. Of 15 untreated fetuses either with AV prolongation between 2 and 6 z-scores or with type 1 second-degree block, progressive heart block developed in none of them. Three of these 15 fetuses (20%) had a neonatal diagnosis of first-degree block that spontaneously resolved (n = 2) or has not progressed (n = 1) on follow-up examinations. No other cardiac complications were detected.
CONCLUSIONS:
Fetal AV prolongation did not predict progressive heart block to birth. Our findings question the rationale of a management strategy that relies on the early identification and treatment of fetal AV prolongation to prevent CAVB.
AuthorsEdgar T Jaeggi, Earl D Silverman, Carl Laskin, John Kingdom, Fraser Golding, Roland Weber
JournalJournal of the American College of Cardiology (J Am Coll Cardiol) Vol. 57 Issue 13 Pg. 1487-92 (Mar 29 2011) ISSN: 1558-3597 [Electronic] United States
PMID21435519 (Publication Type: Journal Article)
CopyrightCopyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Antibodies, Antinuclear
Topics
  • Antibodies, Antinuclear (blood)
  • Atrioventricular Block (congenital, diagnosis, immunology)
  • Atrioventricular Node (physiopathology)
  • Echocardiography
  • Electrocardiography
  • Female
  • Humans
  • Pregnancy
  • Prospective Studies
  • Sensitivity and Specificity
  • Ultrasonography, Doppler, Pulsed

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: